MDLN Medline Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 2046386 · Fiscal year ends 12/31
Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin25.7%
Operating margin5.7%
Net margin1.9%
FCF margin6.2%
EBITDA margin9.0%
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets51.7%
Debt / equity1.07x
Current ratio4.04x
Interest coverage2.50x
Cash quality & payout
Operating cash flow / net income4.13x
Accruals ratio—
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY2025*2025-12-16 | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $28.43B | — | $25.51B | $23.23B |
| Cost of revenue | $20.91B | — | $18.53B | $17.35B |
| Gross profit | $7.52B | — | $6.98B | $5.88B |
| R&D expense | $80.00M | — | $67.00M | $60.00M |
| SG&A expense | $4.52B | — | $4.11B | $3.87B |
| Operating income | $2.21B | — | $2.15B | $1.25B |
| Interest expense | $945.00M | — | $1.14B | $1.21B |
| Pretax income | $1.25B | — | $1.25B | $264.00M |
| Income tax | $91.00M | — | $46.00M | $30.00M |
| Net income | $1.16B | $1.15B | $1.16B | $234.00M |
| EBITDA | $3.22B | — | $3.12B | $2.20B |
| EPS (basic) | -0.01 | — | — | — |
| EPS (diluted) | -0.01 | — | — | — |
| Weighted avg. shares (diluted) | 810.00M | — | — | — |
| Balance sheet | ||||
| Cash & equivalents | $1.94B | — | $250.00M | $1.58B |
| Short-term investments | $0 | — | — | — |
| Receivables | $3.53B | — | $3.22B | — |
| Inventory | $4.77B | — | $4.46B | — |
| Current assets | $10.68B | — | $8.27B | — |
| PP&E, net | $4.78B | — | $4.59B | — |
| Goodwill | $8.08B | — | $8.06B | $7.53B |
| Intangibles | $13.89B | — | $14.56B | — |
| Total assets | $38.48B | — | $35.98B | — |
| Current liabilities | $2.49B | — | $2.44B | — |
| Short-term debt | $77.00M | — | $78.00M | — |
| Long-term debt | $12.48B | — | $16.42B | — |
| Total debt | $12.56B | — | $16.49B | — |
| Total liabilities | $19.20B | — | $19.45B | — |
| Shareholders' equity | $10.74B | — | — | — |
| Net debt | $10.62B | — | $16.24B | — |
| Cash flow statement | ||||
| Operating cash flow | $1.74B | — | $1.77B | $1.69B |
| Capital expenditure | $447.00M | — | $354.00M | $275.00M |
| Free cash flow | $1.30B | — | $1.42B | $1.41B |
| Investing cash flow | -$474.00M | — | -$1.49B | -$312.00M |
| Financing cash flow | $399.00M | — | -$1.61B | -$191.00M |
| Depreciation & amortization | $1.01B | — | $977.00M | $951.00M |
| Stock-based compensation | $76.00M | — | $61.00M | $78.00M |
| Share buybacks | $33.00M | — | $20.00M | $0 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.